-Sep) operating results based on its reviewed consolidated financial statements ended September 30, 2019 as follows. Highlights on Q3-2019 Operating results Unit : Million Baht Q3-19 Q3-18 Q2-19 % Change

Q1-2020 (Jan-Mar) operating results based on its reviewed consolidated financial statements ended 31 March 2020 as follows. Highlights on Q1-2020 Operating Results Unit : Million Baht Q1-20 Q1-19 Q4-19

November 13, 2006 May 15, 2020 Subjects : Clarification of Operating Performance for the Q1/2020 Attention : The Director and Manager of the Stock Exchange of Thailand The Consolidated net profit of

Operation : Consolidated Profit & Loss Statement 4Q 4Q % 12 mth 12 mth % Unit : THB million 2019 2018 change 2019 2018 change Revenue from non-social security 285.64 220.70 29% 1,041.26 911.16 14% Revenue

Position : Consolidated Balance Sheet Sep Sep Dec Sep.17- Sep.17- Unit : THB million 2017 2016 2016 Sep.16 Dec.16 Cash and temporary investments 593.05 775.09 711.34 -23% -17% Trade receivables 279.13 236.56

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

per visit increased to over THB 1,600. Despite the slight Operation : Consolidated Profit & Loss Statement 1Q 1Q % Unit : THB million 2019 2018 change Revenue from non-social security 248.35 218.24 14

declined yoy whereas revenue per head remained on the rise. The increase of revenue per head was Operation : Consolidated Profit & Loss Statement 3Q 3Q % 9 mth 9 mth % Unit : THB million 2019 2018 change

auditor as follows: Statements of Comprehensive Income for the 2nd Quarter Ended June 30, 2020 Operation : Consolidated Profit & Loss Statement 2Q 2Q % Unit : THB million 2020 2019 change Revenue from Non

follows: Statements of Comprehensive Income for the 1st Quarter Ended March 31, 2020 Revenue from Hospital Operations Operation : Consolidated Profit & Loss Statement 1Q 1Q % Unit : THB million 2020 2019